Treat-to-Target in Ulcerative Colitis: How Soon Is Now?
Journal of Clinical Medicine · 16.01.2026 · 15 (2) · 759
DOI: 10.3390/jcm15020759 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.01.2026. Verfasst von Laura Parisio und 6 weiteren Autor:innen. Beteiligte Einrichtung: UOS Gastroenterologia, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ulcerative colitis (UC) is a chronic progressive inflammatory bowel disease, with evolutive potential for extension to the entire colon, development of complications and need for colectomy. Therapeutic goals in UC have moved from symptom control to more stringent outcomes such as endoscopic and histologic remission, which have been observed to correlate with improved long-term outcomes. Disease clearance, a composite endpoint simultaneously including clinical remission, endoscopic and histologic healing, has been recently proposed as the ultimate target. A treat-to-target approach, as endorsed by the STRIDE II consensus, with a tight monitoring and treatment escalation when predefined endpoints are not reached, is proposed as a strategy to achieve complete disease control. However, unlike Crohn’s disease (CD), the evidence supporting this approach for the management of UC is limited and its implementation in routine clinical practice is not widely diffused. Recent real-life data show that almost half of UC patients are not adequately controlled with current therapies according to STRIDE II criteria, due to steroid overuse, persistent signs of inflammation, active extra-intestinal manifestations and impaired quality of life. This perspective paper explores current evidence and future directions on treat-to-target strategies in UC for clinical research and practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UOS Gastroenterologia, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy.
- Dipartimento di Diagnostica per Immagini e Radioterapia Oncologica, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.
- UOC Pronto Soccorso, Medicina d'Urgenza e Medicina Interna, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy.
- UOC di Radioterapia Oncologica ed Ematologia, Dipartimento di Diagnostica per Immagini, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.
- Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
ORCID-Profile: Giuseppe Cuccia, Luigi Carbone, Laura Maria Minordi, Daniela Pugliese
Zitieren
APA
Parisio, L., Cuccia, G., Privitera, G., Castaldo, F., Carbone, L., Minordi, L. M., & Pugliese, D. (2026). Treat-to-Target in Ulcerative Colitis: How Soon Is Now?. Journal of Clinical Medicine, 15(2), 759. https://doi.org/10.3390/jcm15020759
Vancouver
Parisio L, Cuccia G, Privitera G, Castaldo F, Carbone L, Minordi LM, et al. Treat-to-Target in Ulcerative Colitis: How Soon Is Now?. Journal of Clinical Medicine. 2026;15(2):759. doi:10.3390/jcm15020759
BibTeX
@article{Parisio2026,
author = {Parisio, Laura and Cuccia, Giuseppe and Privitera, Giuseppe and Castaldo, Federico and Carbone, Luigi and Minordi, Laura Maria and Pugliese, Daniela},
title = {Treat-to-Target in Ulcerative Colitis: How Soon Is Now?},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {2},
pages = {759},
doi = {10.3390/jcm15020759}
}
EUVIMED